The OIE Relevant Standards and Guidelines for Vaccines

GALVMED/OIE STAKEHOLDER WORKSHOP ON THE HARMONISATION OF THE REGISTRATION OF VETERINARY MEDICINAL PRODUCTS, JOHANNESBURG, SOUTH AFRICA 9-11 MAY 2017

Dr Mária Szabó
OIE Science and New Technologies Department, Paris, France
Outline

Veterinary legislation Chapter 3.4 The role of Official Bodies in the International Regulation of Veterinary biologicals (Terrestrial Animal Health Manual)

Standards and guidelines related to Veterinary Medicinal Products (VMPs), primarily for vaccines and diagnostic tests

Recent Updates
Standards and Guidelines Related to Vaccines
The OIE Standards

**CODES**
- Terrestrial
- Aquatic

**MANUALS**
- Terrestrial
- Aquatic
3.7 Recommendations for the Manufacture of Vaccines (new)

Now available online, and the printed version is scheduled for release late 2018 can be purchased directly at pub.sales@oie.int.

http://www.oie.int/en/international-standard-setting/terrestrial-manual/access-online/
Resolution No. 13 Amendments to the Manual of Diagnostic Test and Vaccines for Terrestrial Animals (Terrestrial Manual):

3.7. Recommendations for the manufacture of vaccines

- 3.7.1. Minimum requirements for the organisation and management of a vaccine manufacturing facility (new)
- 3.7.2. Minimum requirements for the production and quality control of vaccines (new)
- 3.7.3. Minimum requirements for aseptic production in vaccine manufacture (new)
Terrestrial Manual - Relevant standards

Provides generic and specific guidance on vaccine production and testing:

- Chapter 1.1.8 Principles of veterinary vaccine production (including diagnostic biologicals) (New version adopted in 2015)

- Chapter 1.1.9 Tests of biological materials for sterility and freedom from contamination (Currently being revised. To be developed in consultation with VICH counterparts. The revised chapter incorporating Member Countries’ comments will be proposed for adoption in 2017)
Principles of Veterinary Vaccine Production

• **Background**: A reliable supply of pure, safe, potent and effective vaccines is essential for maintenance of animal health and the successful operation of animal health programmes.

• **Objective**: to ensure the production and availability of uniform and consistent vaccines of high and assured quality.

• **Contents**: General requirements and procedures.

• **Nomenclature**: for this chapter, the term “vaccine” includes “all products designed to stimulate active immunisation of animals against disease, without regard to the type of microorganism or microbial toxin from which they may be derived or that they contain.”
Terrestrial Manual: Chapter 1.1.8

Summary of the contents:

VACCINE PRODUCTION:

1. Quality Assurance
2. Production facilities
3. Documentation of manufacturing process and record keeping
4. Production
5. Process validation
6. Stability tests
7. Test to demonstrate safety and efficacy of a vaccine
Summary of the contents (cont’d)

7.1. SAFETY TEST

7.1.1. Target animal safety tests
7.1.2. Increase in virulence tests
7.1.3. Assessing risk to the environment

7.2. EFFICACY TEST

7.2.1. Laboratory efficacy
7.2.2. Interference test
7.2.3. Field (safety and efficacy)
    7.2.3.2. Additional requirement for live rDNA products

8. Updating the Production Outline (materials and methods)
Quality Controls (QC) in vaccine production:

- **Principle** (The independence of quality control from production is considered fundamental to the satisfactory operation)
- **Batch/serial release for distribution**
  - Batch/serial purity test
  - Batch/Serial safety test
  - Batch/Serial potency test
- **Other certification and tests**
  - Tests or certification on starting materials or finished products
    - Purity
    - Freedom from extraneous agents
    - TSE certification for material of animal origin
Quality Controls (QC) in vaccine production:

- **Inspection** of Production Facilities: The onsite inspections should be carried out on a regular basis.

- Monitor the manufacturing and quality control procedures.

- Assess conformance to current good manufacturing practices standards (e.g., EU GMP, United States Code of Federal Regulations, PIC/S)

- PIC/S: The Pharmaceutical Inspection Cooperation Scheme
Summary of the contents (cont’d)

Two Appendices:

1. Risk analysis for biologicals for veterinary use (provides general considerations)

2. Risk analysis for veterinary vaccines:
   Introduction – Principles – Manufacturing practices – Information to be submitted when applying for Marketing Authorisation (MA) in the importing country – Categorisation of veterinary vaccines – Vaccinovigilance – Risk communication
TESTS FOR STERILITY AND FREEDOM FROM CONTAMINATION OF BIOLOGICAL MATERIALS

Approved by the Biological Standards Commission to be sent to Member Countries for second-round comment and proposal for adoption in May 2017

Successful implementation of this Standard will be dependent on comments and contributions from different stakeholders, such as National Focal Points for Veterinary Products for OIE Delegates and how manufacturers put into practice.

VICH Biologics Quality Monitoring Expert Working Group (BQM-EWG) provided inputs-to be harmonized as much as possible in the future with VICH extraneous agents guidelines.
Current version of the Chapter 1.1.9

Structure:

A. GENERAL PROCEDURES
B. LIVING VIRAL VACCINES FOR ADMINISTRATION BY INJECTION
C. LIVING VIRAL VACCINES FOR ADMINISTRATION THROUGH DRINKING WATER, SPRAY, OR SKIN SCARIFICATION
D. INACTIVATED VIRAL VACCINES
E. LIVING BACTERIAL VACCINES
F. INACTIVATED BACTERIAL VACCINES
G. SERA and DIAGNOSTIC AGENTS FOR ADMINISTRATION TO ANIMALS
H. EMBRYOS, OVA, SEMEN AND GENETICALLY MODIFIED ORGANISM
I. PROTOCOL EXAMPLES
Outline of vaccine section of the disease chapters

1. Background

2. Outline of production and minimum requirements for vaccines
   2.1. Characteristics of the seed
       1. Biological characteristics
       2. Quality criteria (*sterility, purity, freedom from extraneous agent*)
       3. Validation of the vaccine strain
       4. Emergency procedure for provisional acceptance of new master seed virus
   2.2. Method of manufacture
       o Procedure
       o Requirements for ingredients
       o In process controls
       o Final product batch tests (*sterility, identity, safety, bath potency*)
   2.3. Requirements for authorisation/registration/licencing

3. Specific topics (the e.g. oral vaccine, toxoid, specific requirements for biotechnology based vaccines)
Outline of vaccine section of the disease chapters (2)

Production and minimum requirements for vaccines

2.3. Requirements for authorisation/registration/licencing

2.3.1. Manufacturing process

2.3.2. Safety requirements

2.3.3. Efficacy requirements

2.3.4. Vaccines permitting DIVA strategy (DIVA vaccines permit differentiation of infected versus vaccinated animals)

2.3.5. Duration of immunity

2.3.6. Stability
Specific Recommendations

3.1. Laboratory methodologies for bacterial antimicrobial susceptibility testing

3.2. Biotechnology in the diagnosis of infectious diseases

3.3. The application of biotechnology to the development of veterinary vaccines

3.4. The role of official bodies in the international regulation of veterinary biologicals
Recent Updates (1)

Waiving or not waiving Target Animal Batch Safety Tests (TABST)?

- The OIE Biological Standard Commission, concluded that, rather than completely eliminating all references to the TABST, references to the TABST in the Terrestrial Manual should be revised to include a note that the prescribed TABST could be eliminated in situations where other quality control measures are in place.
Recent Updates (2)

Reasons

• Potential variability of quality assurance systems employed by manufacturers in OIE Member Countries

• Potential for residual toxicity of some vaccines

It would be inappropriate to completely eliminate all references to the TABST in OIE guidelines such as the Terrestrial Manual
Recent Updates (3)

Request for an refined OIE definition of thermostable or thermoresistant vaccines

- Benefit of access to: science-based, pragmatic standards to objectively characterise the thermotolerant properties of vaccines
- There is much interest in characterising the thermotolerant properties of existing vaccines and developing new formulations
- Need revised pertinent definition(s) for thermotolerant vaccines to revise or expand the OIE Manual’s definition on thermotolerance
- Need to define relevant parameters of thermotolerance for label claims for various types of veterinary vaccines (e.g. conventional live or killed vaccine or a new generation thermotolerant vaccine)
Conclusion

• We need to continue to work together to have high quality, practical global standards and guidelines for veterinary medicinal products

• We need to build the capacity to respond to the new challenges, like how we respond to emerging diseases?

• How can the OIE contribute in helping you to implement the standards and guidelines?
Thank you for your attention!